# Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

> **NCT03871153** · PHASE2 · TERMINATED · sponsor: **Greg Durm, MD** · enrollment: 7 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Stage III Non-small-cell Lung Cancer

## Interventions

- **DEVICE:** Durvalumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **RADIATION:** Radiation
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT03871153
- **Lead sponsor:** Greg Durm, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-02
- **Primary completion:** 2021-10-30
- **Final completion:** 2022-03-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Investigator decided to halt study due to low accrual.
- **Last updated:** 2023-11-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03871153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03871153, "Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03871153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*